Episode
A follow-on conversation with Drs. Lawhern & Nadeau, delving deeper into opioid mortality statistics
We continue the conversation and delve further into opioid mortality statistics, exposing misrepresentations and debunking purported causal relationships between opioid ...
A conversation with Dr. Parker, a model of physician advocacy
Dr. Parker's journey began with four years of dedicated service in the U.S. Marine Corps, where he earned accolades such ...
Dr. Amesh Adalja Discusses Flu Season and Trends in 2024
Dr. Adalja shares his thoughts on the current flu season and future trends in viral infectious diseases. He talks about ...
Drs. Lawhern and Nadeau Explain Overdose Mortality Data
Drs. Red Lawhern and Stephen Nadeau discuss the statistics behind overdose mortality. They discern different causes of overdoses, differentiating prescription ...
A conversation with Dr. Gavin Francis
We speak with famed physician-writer, Dr. Gavin Francis, and discuss his book, Recovery: The Lost Art of Convalescence. You can ...
A conversation with Miss VJ Gray, a chronic pain patient and advocate
We speak with Miss VJ Gray, a clinically trained researcher who uses data to drive advocacy. #burdenofpain
A conversation with Kim, a chronic pain patient
We speak with Kim, who shares her story of medical neglect and patient abandonment. #burdenofpain
A conversation with Milissa, chronic pain patient
Milissa is a college graduate with a bachelor degree in Economics and played D1 tennis before moving on to the ...
A conversation with Mr. Bill Murphy, chronic pain patient advocate
We speak with Mr. Bill Murphy, a chronic pain patient and patient advocate who helps other patients with chronic pain ...
A conversation with Mr. Tom Hayashi, chronic pain patient advocate
We speak with Mr. Tom Hayashi, a chronic pain patient advocate who strives to provide his wife, a chronic pain ...
A conversation with Dr. Felix Brizuela
We speak with Dr. Felix Brizuela, a physician fighting for medical autonomy after having his career and personal life destroyed ...
A conversation with Dr. Jane Orient of AAPS
We speak with Dr. Jane Orient, media contact for the Association of American Physicians and Surgeons (AAPS). AAPS is a ...
BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us
Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...
Read more